Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221.
- DOI
- 10.1158/1078-0432.ccr-19-0298
- Published
- 2019 Oct 15
- Container
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1158/1078-0432.ccr-19-0298,
title = {Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221.},
author = {Tinker AV and Hirte HW and Provencher D and Butler M and Ritter H and Tu D and Azim HA Jr and Paralejas P and Grenier N and Hahn SA and Ramsahai J and Seymour L},
year = {2019},
journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
doi = {10.1158/1078-0432.ccr-19-0298},
url = {https://doi.org/10.1158/1078-0432.ccr-19-0298}
}RIS
TY - JOUR TI - Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221. AU - Tinker AV AU - Hirte HW AU - Provencher D AU - Butler M AU - Ritter H AU - Tu D AU - Azim HA Jr AU - Paralejas P AU - Grenier N AU - Hahn SA AU - Ramsahai J AU - Seymour L PY - 2019 JO - Clinical cancer research : an official journal of the American Association for Cancer Research DO - 10.1158/1078-0432.ccr-19-0298 UR - https://doi.org/10.1158/1078-0432.ccr-19-0298 ER -
APA
AV, T., HW, H., D, P., M, B., H, R., D, T., Jr, A. H., P, P., N, G., SA, H., J, R., & L, S. (2019). Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-0298
Source records
- pubmed · retrieved 2026-09-27T15:12:59.575Z